Characteristic | Placebo + MTX, n = 133 | Golimumab 100 mg + Placebo, n = 133 | Golimumab 50 mg + MTX, n = 89 | Golimumab 100 mg + MTX, n = 89 |
---|---|---|---|---|
Female sex, no. (%) | 109 (82.0) | 105 (78.9) | 72 (80.9) | 72 (80.9) |
Age, yrs | 51.2 ± 12.0 | 50.0 ± 11.5 | 50.3 ± 11.0 | 50.0 ± 10.8 |
Duration of RA, yrs | 8.6 ± 7.9 | 8.3 ± 7.9 | 7.3 ± 7.8 | 9.0 ± 8.3 |
Patient’s assessment of disease activity (0–10 cm VAS) | 5.4 ± 2.5 | 5.5 ± 2.3 | 5.8 ± 2.4 | 5.6 ± 2.5 |
HAQ-DI score (0–3) | 1.3 ± 0.7 | 1.3 ± 0.7 | 1.4 ± 0.7 | 1.4 ± 0.7 |
SF-36 | ||||
PCS score (0–100) | 31.6 ± 8.3 | 30.9 ± 8.5 | 30.5 ± 8.4 | 29.9 ± 8.0 |
MCS score (0–100) | 43.9 ± 10.3 | 43.9 ± 11.2 | 44.1 ± 10.6 | 43.2 ± 11.8 |
FACIT-Fatigue (0–52) | 28.7 ± 10.5 | 27.9 ± 10.6 | 26.6 ± 11.0 | 26.6 ± 10.3 |
Data are mean ± SD unless otherwise noted. FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy; HAQ-DI: Disability Index of the Health Assessment Questionnaire; MCS: mental component summary; MTX: methotrexate; PCS: physical component summary; RA: rheumatoid arthritis; SF-36: Medical Outcomes Study Short Form-36; VAS: visual analog scale.